Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid and BioMerieux to Develop, Market Sepsis Assays

NEW YORK (GenomeWeb News) — Cepheid and BioMerieux plan to develop and market a line of sepsis tests, the companies said today.
 
The companies said they will develop assays to identify fungi and bacteria and genetic markers for antibiotic resistance. Cepheid and BioMerieux also said that the panel could be used to identify hospital-acquired pneumonia.
 
The tests will work on Cepheid’s GeneXpert platform. Cepheid will manufacture them and BioMerieux will distribute them worldwide.
 
As part of the deal, BioMerieux has licensed Cepheid patents for its methicillin-resistant Staphylococcus aureus test. Cepheid will continue to develop, manufacture, and market the products
 
Financial terms of the agreement were not released.
 
Sepsis is a bacterial infection of the bloodstream that affects a small percentage of hospital patients, generally those with depressed immune systems. The condition affects around 750,000 Americans each year and results in death in between a quarter and a half of them. US hospitals $17 billion a year treating the infections, the companies said.
 
Cepheid CEO John Bishop said a rapid sepsis test coupled with a “molecular snapshot of drug-resistant organisms” will allow doctors to make better treatment decisions more quickly.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.